Conference Description:

At the SMi's Immuno-Oncology Conference participants will get:

Agenda - Valuable time is spent to discover the latest trends and hottest topics in the industry to provide the best possible agenda for attendees. 15+ engaging presentations/case studies/keynote addresses, including:

- Targeting immune checkpoints with Humabody VH therapeutics
- Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy
- Tumour mutation burden and the potential of its use as an indication of treatment choice
- Unwanted immunogenicity and functionality testing of immuno-oncology drugs
- New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology

Speakers - Top representation of industry leaders. 15+ leading experts in Immuno-Oncology field, including

- James Legg, Vice President R&D, Crescendo Biologics
- Andrew Exley, Medical Assessor, MHRA
- Harry Smith, Medical Scientist, Gilead Sciences
- Grace Macaulay, Global Safety Physician Patient Safety Oncology, MedImmune
- David Giljohan, CEO, Exicure
- Kandeepan Ganeshalingam, Executive Director, Oncology Therapeutic Area Head, European Clinical Development, MSD
- Rochana Wickramasinghe, Director of Oncology Evaluation, AstraZeneca

Workshops - Carefully selected topics for further on-sight training. 2 pre-conference workshops to provide in-depth knowledge on specific topics:

- Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by LucidQuest Ventures
- Could the Microbiome boost Cancer Immuno-Therapy - hosted by ImmuneBiotech and Lund University

Networking - it is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation.

Brochure https://go.evvnt.com/223727-2?pid=154
Twitter https://go.evvnt.com/223727-3? pid=154

Prices:
Immuno-Oncology - Main Conference | STANDARD PRICE: GBP 1499.0
WORKSHOP | Strategic Competitive Intelligence in the Immuno-Oncology space: GBP 599.0
WORKSHOP | Could the Microbiome boost cancer immunotherapy?: GBP 599.0

Speakers: AMAN SINGH PK-PD Scientist, Janssen, ANDREW EXLEY Medical Assessor, MHRA, CAROLINE HULL Research Associate, Kings College London, CHRISTOPHER PERRETT Regulation Manager, Human Tissue Authority, DAVID GILJOHANN CEO, Exicure Inc., GRACE MACAULAY Global Safety Physician, Patient Safety-Oncology, MedImmune, HARRY SMITH Medical Scientist, Gilead Ltd, JAMES HARPER Scientist II, MedImmune Oncology Inc., JAMES LEGG Vice President R&D, Crescendo Biologics Ltd, JONATHAN ZALEVSKY Senior Vice President Biology & Preclinical Development, Nektar Therapeutics, JONATHAN WAN MD, PhD Student, Cancer Research UK, KANDEEPAN GANESHALINGAM Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited, PHILIP HOWARD Chief Scientific Officer, Spirogen, ROCHANA WICKRAMASINGHE Evaluation Director, AstraZeneca, SCOTT ROBBINS Principal Scientist, MedImmune Oncology Inc., SOFIE PATTIJN Chief Technology Officer, ImmunXperts

Time: on Wednesday September 26, 2018 at 9:00 am (ends Thursday September 27, 2018 at 6:00 pm)